- Company
- Roche’s Lunsumio and Columvi win approval in Korea
- by Jan 5, 2024 05:41am
- Roche's Lunsumio and Columvi are the first bispecific antibodies for lymphoma treatment, showing effectiveness as a third-line treatment for patients with lymphoma. These two drugs are highly regarded for their clinical advantages, as they have additional specific antigen-binding sites compared to monoclonal antibodies. Roche Korea hel
- Company
- Pharma CEOs consider job cuts and reducing hiring in 2024
- by Kim, Jin-Gu Jan 5, 2024 05:41am
- 13% of pharmaceutical and bio company CEOs have announced plans to reduce employment this year. Apart from this, another 12% have indicated the possibility of reducing their workforce this year. Overall, the industry held a more cautious stance toward hiring this year. Compared to last year, the number of respondents who responded that
- Company
- Koselugo commences prescription with insurance coverage
- by Eo, Yun-Ho Jan 5, 2024 05:41am
- Hospitals have started prescribing Koselugo, a treatment for pediatric neurofibromatosis. AstraZeneca Korea’s Koselugo (ingredient: selumetinib), a neurofibromatosis, has recently passed the Drug Committee (DC) of tertiary hospitals, including Seoul National University Hospital, Samsung Seoul Hospital, Seoul St. Mary's Hospital, Seoul
- Company
- Celltrion to divest prescription drugs acquired from Takeda
- by Kim, Jin-Gu Jan 4, 2024 05:33am
- The Celltrion group is selling divestiture of primary care business rights in the Asia-Pacific region acquired from Takeda Pharmaceutical in 2020. Among the business rights acquired from the previous deal, Celltrion group will initiate the sales of business rights for prescription drugs, excluding those intended for the domestic market
- Company
- Industry is less inclined to expand investment this year
- by Kim, Jin-Gu Jan 4, 2024 05:33am
- One in four CEOs of pharma and biotech companies announced that they will expand their investment in 2024. This is down by half compared to the response received in the survey last year when one in two CEOs said they would expand investment. This is likely a reflection of the growing economic uncertainty in Korea and abroad. 1 in
- Company
- New CKD drug Kerendia is expected to receive reimb soon
- by Eo, Yun-Ho Jan 4, 2024 05:33am
- New chronic kidney disease drug ‘Kerendia’ is expected to receive reimbursement status. According to the industry, Bayer has reached a settlement with National Health Insurance Service (NHIS) in negotiations for the reimbursement pricing of its drug Kerendia(finerenone), which is used to treat chronic kidney disease in patients with t
- Company
- Only 1 of 10 CEOs ‘positive’ about drug regulations in KOR
- by Chon, Seung-Hyun Jan 3, 2024 07:28pm
- A survey showed only 1 in 10 CEOs of pharmaceutical companies were found to be satisfied with the Korean health authorities' regulatory policies for the pharmaceutical industry. In all major regulatory areas such as approvals, drug pricing, and sales, the satisfaction rate of CEOs was more negative than positive towards the set regulations.
- Company
- New antibiotic to be listed for reimb, following Zerbaxa
- by Eo, Yun-Ho Jan 3, 2024 05:40am
- Zavicefta, the next-generation antibiotic, is progressing towards reimbursement listing. According to the industry, Pfizer Pharmaceutical Korea is currently in the final round of discussions with the National Health Insurance Service (NHIS) to settle the reimbursement pricing negotiations for its Zavicefta Inj (ceftazidime·avibactam).
- Company
- ‘Drug pricing and reimb' needs most regulatory improvement
- by Chon, Seung-Hyun Jan 3, 2024 05:40am
- CEOs of both domestic and multinational pharmaceutical companies alike identified 'drug prices and reimbursement as in need of most regulatory improvement. CEOs of multinational pharmaceutical companies only gave a 2-point range satisfaction score in terms of satisfaction with Korea’s drug pricing and reimbursement regulations. This indica
- Company
- SK Chemicals ends copromotion agreement with Eli Lilly
- by Lee, Tak-Sun Jan 2, 2024 05:45am
- SK Chemicals announced that its copromotion agreement with Lilly Korea for the antidepressant Cymbalta Cap (duloxetine hydrochloride) and the migraine treatment Emgality (galcanezumab-gnlm) has been brought to an end. Cymbalta is the number one selling antidepressant on the market. Sales of Emgality have also been rising since last year'
